Objective
While short course chemotherapy for drug-susceptible tuberculosis (TB) remains effective, it is relatively inefficient by modern pharmaceutical standards and universally menaced by the dissemination of multidrug-resistant (MDR), extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis (M.tb) and synergy with the HIV/AIDS pandemic. Since one third of the world’s population is latently infected with M.tb successful anti-TB drugs must be able to eliminate persistent bacilli from the reservoir, which makes TB therapy more challenging.
Most of the current antibiotics typically kill M.tb rather than targeting bacterial systems important in the virulence of the bacteria and manipulation of the host-specific biochemical pathways.
Whereas normally the host immune system is able to destroy invading bacilli, M.tb developed a wide palette of strategies to avoid bactericidal host responses. The major and most studied virulence mechanism of the tuberculosis pathogen is the ESX-1 system, a type VII secretion system which clearly plays an important role in the pathogenicity and the host-pathogen interaction. The ESX-1 system modulates the host defence through different ways like phagosome maturation arrest, inhibition of TLR signalling in macrophages, macrophage apoptosis induction, and interaction with laminin.
The here proposed project forms part of a multidisciplinary anti-virulence drug discovery program focusing on the identification of important host cell signalling pathways that are involved in the pathogenesis, entry and intracellular survival of M.tb. Anti-virulence drugs inhibit bacterial targets that interfere with host cell defence pathways during infection or block host signalling pathways modulated by the bacteria, thus defending the host from the pathogen. This novel strategy of anti-virulence drug discovery is a potential alternative to antibiotics, which may be used in combination therapies to shorten TB treatment and prevent resistance.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciences basic medicine pharmacology and pharmacy drug discovery
- medical and health sciences health sciences infectious diseases RNA viruses HIV
- medical and health sciences clinical medicine pneumology tuberculosis
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs antibiotics
- medical and health sciences basic medicine pharmacology and pharmacy drug resistance multidrug resistance
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP7-PEOPLE-2012-IEF
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
1015 LAUSANNE
Switzerland
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.